Since RSK is involved in the control of mRNA translation and is also a potent modulator of inflammation through the TRAF6-IKK-NF-κB pathway (Zhang et al, 2005; Peng et al, 2010; Yao et al, 2018), we hypothesize that RSK inhibition in melanoma may globally reduce the bioenergetic charge and associated oxidative stress in melanoma cells. This evidence concerns the gene RPS6KA1 and melanoma.